Description; General description; Tumor protein p53 binding protein (T153BP1) is mapped to human chromosome 15q15.3.[1] It has methylated histone-binding module and tandem tudor domains.[2]; Immunogen; synthetic peptide corresponding to amino acids 1955-1972 of human 53BP1, conjugated to KLH via an N-terminal added cysteine residue. This sequence is conserved in mouse, and differs from rat by one amino acid; Application; Anti-53BP1 (C-terminal) antibody produced in rabbit has been used in western blotting[5] and immunoprecipitation; Physical form; Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.; Disclaimer; Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.; Biochem/physiol Actions; Tumor protein p53 binding protein (T153BP1) has a close link to ataxia-telangiectasia mutated (ATM)-regulated events. 53BP1 becomes phosphorylated by ATM in a DNA damage-dependent manner suggesting that it participates in propagating the ATM signaling to its downstream effectors. T153BP1 also plays a key role in DNA repair by mediating nonhomologous end-joining (NHEJ) near double stranded breaks (DSBs).[3] Fusion of T153BP1 with platelet-derived growth factor receptor beta (PDGFRβ) is implicated in a type of myeloproliferative disorder accompanied with eosinophilia.[4]